CAR-T player Poseida marches on with $30.5M Series B; Kymera inks discovery deal with GSK
→ Investors have infused $30.5 million in Series B cash into Poseida Therapeutics’ pipeline of autologous T cell and NK cell therapies. Using its gene …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
